Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BT-2002
- Development stage
- Unknown
- Lead developer
- Nanjing Drum-Tower Hospital
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
BT-2002 is an individualized neoantigen mRNA vaccine formulated in lipid nanoparticles (LNPs). Developed by Gulou Hospital Affiliated to Nanjing University Medical School, it is designed to treat non-small cell lung cancer (NSCLC) by stimulating a patient-specific immune response. The vaccine is customized for each patient by identifying unique tumor mutations (neoantigens) through genomic sequencing and encoding these targets into mRNA. Once administered, the mRNA is translated into neoantigen proteins that are presented to the immune system, activating T cells to recognize and destroy tumor cells. BT-2002 is currently being investigated in Phase I clinical trials for patients with resected early-stage NSCLC and advanced driver-positive NSCLC, both as a monotherapy and in combination with targeted therapies.
- Other names
- BT-2002 individualized neoantigen mRNA vaccineBT2002 individualized neoantigen mRNA vaccineBT 2002 individualized neoantigen mRNA vaccine
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on BT-2002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BT-2002.